面肩肱型肌营养不良症的CLIA实验室检测:回顾性分析
该研究回顾性分析爱荷华大学分子病理实验室2015年1月至2019年7月全部FSHD检测结果,采用限制性内切酶消化和Southern印迹分析并按需行SMCHD1测序。1594例中703例(44.1%)确诊FSHD,其中664例(94.5%)为FSHD1、39例(5.5%)为FSHD2;结论认为FSHD1占基因确诊FSHD的94.5%,且D4Z4重复数呈FSHD1最少、FSHD2居中、非FSHD1,2最多的连续分布。
要点
- FSHD1占基因确诊FSHD的94.5%,FSHD2占5.5%。
- D4Z4重复数中位数:FSHD1为6.0,FSHD2为15.0,非FSHD1,2为28.0。
- 检测需注意临界片段、体细胞嵌合及易位等复杂情况。
核心结论
- FSHD1占基因确诊FSHD病例的94.5%。
- D4Z4重复数呈连续分布,FSHD1最少、FSHD2居中、非FSHD1,2最多。
研究设计与样本
- 回顾性分析爱荷华大学分子病理实验室2015年1月至2019年7月全部FSHD检测,共纳入1594例患者。
- 检测方法为限制性内切酶消化和Southern印迹分析,并按需行SMCHD1测序。
- 病例分类为FSHD1、FSHD2或非FSHD1,2,并记录临界片段、体细胞嵌合、易位及杂交等位基因等情况。
主要发现
- 1594例中703例(44.1%)确诊FSHD。
- 确诊FSHD的703例中,664例(94.5%)符合FSHD1,39例(5.5%)符合FSHD2。
- 全部1594例中,20例(1.3%)有临界大小4q35等位基因,23例(1.5%)为体细胞嵌合,328例(20.9%)发生易位事件。
- 在至少携带1个4q35A等位基因的病例中,D4Z4重复数中位数FSHD1为6.0(IQR 4-7),FSHD2为15.0(IQR 12-22),非FSHD1,2为28.0(IQR 19-40),组间差异显著。
关键数值与推荐
- FSHD1定义:4q35 EcoRI片段大小≤40 kb,对应1-10个D4Z4重复。
- FSHD2定义:存在允许性4q35A等位基因、D4Z4低甲基化及致病性SMCHD1变异。
- 临界EcoRI片段大小定义为41-43 kb,对应11个D4Z4重复。
临床怎么用
- FSHD基因检测应结合Southern印迹评估4q35片段大小与D4Z4重复数,必要时行SMCHD1测序。
- 报告解读需关注临界片段、体细胞嵌合、易位及杂交等位基因等复杂情况。
- D4Z4重复数分布有助于区分FSHD1、FSHD2与非FSHD1,2,但需结合其他标准综合判断。
局限性
- 本研究为单中心回顾性分析,结果外推需谨慎。
- 原文未报告检测灵敏度、特异度及成本效益等数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To summarize facioscapulohumeral muscular dystrophy (FSHD) diagnostic testing results from the University of Iowa Molecular Pathology Laboratory. METHODS: All FSHD tests performed in the diagnostic laboratory from January 2015 to July 2019 were retrospectively reviewed. Testing was by restriction enzyme digestion and Southern blot analysis with sequencing of SMCHD1, if indicated. Cases were classified as FSHD1 (4q35 EcoRI size ≤40 kb; 1-10 D4Z4 repeats), FSHD2 (permissive 4q35A allele, D4Z4 hypomethylation, and pathogenic SMCHD1 variant), or non-FSHD1,2. We also noted cases with borderline EcoRI fragment size (41-43 kb; 11 D4Z4 repeats), cases that meet criteria for both FSHD1 and FSHD2, somatic mosaicism, and cases with hybrid alleles that add complexity to test interpretation. RESULTS: Of the 1,594 patients with FSHD tests included in the analysis, 703 (44.1%) were diagnosed with FSHD. Among these positive tests, 664 (94.5%) met criteria for FSHD1 and 39 (5.5%) met criteria for FSHD2. Of all 1,594 cases, 20 (1.3%) had a 4q35 allele of borderline size, 23 (1.5%) were somatic mosaics, and 328 (20.9%) had undergone translocation events. Considering only cases with at least 1 4q35A allele, D4Z4 repeat number differed significantly among groups: FSHD1 cases median 6.0 (interquartile range [IQR] 4-7) repeats, FSHD2 cases 15.0 (IQR 12-22) repeats, and non-FSHD1,2 cases 28.0 (IQR 19-40) repeats. CONCLUSION: FSHD1 accounts for 94.5% of genetically confirmed cases of FSHD. The data show a continuum of D4Z4 repeat numbers with FSHD1 samples having the fewest, FSHD2 an intermediate number, and non-FSHD1,2 the most.
引用
- Rieken A, Bossler AD, Mathews KD, et al. CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis. Neurology. 2020. PMID: 33443126. doi:10.1212/WNL.0000000000011412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。